Pfizer begins plan to challenge Shingrix with an mRNA vaccine

Quote












They are still in early testing. I think the mRNA angle is more of a liability than a benefit. Also, Anything less than 90% efficacy isn’t going to go over very well. Lastly, our long term data is pretty solid. I’m not too concerned that they will come in and take our business.
 






anonymous said:
They are still in early testing. I think the mRNA angle is more of a liability than a benefit. Also, Anything less than 90% efficacy isn’t going to go over very well. Lastly, our long term data is pretty solid. I’m not too concerned that they will come in and take our business.
Click to expand...

MRNA = Murders Really Not Acknowledged
 










































Top Bottom
Back
Quote